The role of TAP and MHC class I expression in the response to melanoma immunotherapy using autolgous dendritic cells

Funded Activity Summary

Treatment for patients with malignant melanoma whose disease has spread, or metastasised, to sites distant from the original melanoma is usually unsuccessful. At this stage of the disease there is no known curative treatment with conventional surgery, radiation or chemotherapy. Occasionally, however, melanoma in its early stages is successfully dealt with by the natural response of the immune system. In these cases, the immune system generates cancer-controlling killer T lymphocytes that enter the melanoma and kill the tumour cells. Killer T lymphocytes are generated by the lymph glands when the immune system is presented with melanoma cell components, or antigens, by specialised cells known as dendritic cells. This project consists of a clinical trial that aims to boost the natural ability of the immune system to generate killer cells by growing dendritic cells from the blood, mixing them with melanoma antigens, and then inject the mixture. When injected into the skin, dendritic cells quickly move to lymph glands to generate killer T lymphocytes. T lymphocytes can find their way to melanoma deposits all over the body. The reasons for response or non-response to the vaccination will particularly be assessed in this project.

Funded Activity Details

Start Date: 01-01-2001

End Date: 01-01-2002

Funding Scheme: NHMRC Project Grants

Funding Amount: $337,811.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Diagnostic radiography

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

TAP/MHC mutations | clinical trial | dendritic cell | immunotherapy | melanoma | tumours

Related Links